Drug Database
Back to search

Netherlands· NL-c6adc0c2a08f

Fostimon 150 IE, poeder en oplosmiddel voor oplossing voor injectie

A urofollitropin product containing urofollitropine, registered in Netherlands by IBSA Farmaceutici Italia S.r.L. The same ATC class is registered in 11 of our 19 countries.

ATC G03GA04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedFostimon 150 IE, poeder en oplosmidde…ATCG03GA04REGISTER NO.NL-c6adc0c2a08fPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about urofollitropineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Urofollitropin is registered in 11 of 19 countries.

Countries holding a registration under ATC G03GA04 (urofollitropin), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose
Search urofollitropin products by name

Urofollitropin · ATC G03GA04

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
UROFOLLITROPINE
Manufacturer
IBSA Farmaceutici Italia S.r.L
Country
Netherlands (NL)
ATC code
G03GA04
ATC class
Urofollitropin
Defined daily dose
75 E, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    33179

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for urofollitropin.

Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check urofollitropin against other medicinesHow interaction checks work

Urofollitropin · interactions on record

1 record

  • 1 moderate

Most severe, free to view

  • GanirelixH01CC01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Urofollitropin in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All urofollitropin products

Authorised across Europe · EMA

The same active substance is authorised in 19 EEA countries. Names it is sold under:

  • Austria · Fostimon, Fostimon Pfs
  • Belgium · Fostimon, Fostimon Kit
  • Bulgaria · Фостимон
  • Cyprus · Fostimon, Fostimon Pfs
  • Czechia · Fostimon
  • Denmark · Fostimon, Fostimon Set
  • Spain · Fostipur, Fostipur Kit
  • Finland · Fostimon, Fostimon Set
  • France · Fostimon, Fostimonkit
  • United Kingdom (Northern Ireland) · Fostimon, Fostimon Pfs
  • Greece · Altermon
  • Hungary · Fostimon Hp
  • Ireland · Fostimon, Fostimon Pfs
  • Italy · Fostimon
  • Luxembourg · Fostimon, Fostimon Kit
  • Norway · Fostimon, Fostimon Set
  • Poland · Fostimon
  • Sweden · Fostimon, Fostimon Set
  • Slovakia · Fostimon Hp

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f9ec0557-e25d-458e-8c06-2f5b7f264860
GET /v1/drugs/f9ec0557-e25d-458e-8c06-2f5b7f264860?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder en oplosmiddel voor oplossing voor injectie",
  "route": "Intramusculair gebruik, Subcutaan gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h33179_smpc.pdf",
  "strength": null,
  "atc_label": "Urofollitropin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg33179",
  "excipients": [
    "LACTOSE 1-WATER",
    "NATRIUMCHLORIDE",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "WATER, GEZUIVERD"
  ],
  "substances": [
    "UROFOLLITROPINE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h33179.pdf",
  "authorised_at": "2006/10/12",
  "procedure_number": "FR/H/0282/002",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "33179",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about urofollitropin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console